| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5605067 | International Journal of Cardiology | 2017 | 40 Pages |
Abstract
LVADs used as BTT did not significantly alter post-transplantation long-term survival, rejection, and post-operative morbidity. LVAD BTT may be cost-effective, particularly in medium and high-risk patients with expected prolonged waiting times, renal dysfunction, and young patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Michael Seco, Dong Fang Zhao, Michael J. Byrom, Michael K. Wilson, Michael P. Vallely, John F. Fraser, Paul G. Bannon,